Eli’s Stock Surges 0.37% on $2.5 Billion Trading Volume Climbs to 33rd in U.S. Liquidity Rankings as Oncology Pipeline and Gene Therapy Partnership Boost Investor Optimism

. 18, 2025, , . equities in daily liquidity. The biopharmaceutical giant’s shares gained momentum amid investor focus on its recent clinical trial updates and regulatory developments.

Analysts noted that Eli’s performance was driven by renewed optimism around its oncology pipeline, . , reinforcing its long-term growth narrative.

. , .

To run this back-test rigorously I need to pin down a few practical details: Universe definition – “Top 500” by volume out of which universe? All U.S. common stocks (NYSE + NASDAQ + Arca) or a narrower list (e.g., , , etc.). ? , . Once I have those three items I can generate the data-retrieval plan and run the back-test.